ACHFF (Arch Biopartners) EPS (Basic) : $-0.01 (TTM As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Arch Biopartners EPS (Basic)?

Arch Biopartners's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.01.

Arch Biopartners's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.01.

Arch Biopartners's EPS without NRI for the three months ended in Mar. 2025 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Arch Biopartners EPS (Basic) Historical Data

The historical data trend for Arch Biopartners's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners EPS (Basic) Chart

Arch Biopartners Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

EPS (Basic)

Get a 7-Day Free Trial

-0.06

-0.02

-0.04

-0.05

Arch Biopartners Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.01	-	-	-0.01

Arch Biopartners EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arch Biopartners's Basic EPS for the fiscal year that ended in Sep. 2024 is calculated as

Basic EPS (A: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.894	-	0)	/	63.381
	=	-0.05

Arch Biopartners's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.435	-	0)	/	65.468
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Arch Biopartners (OTCPK:ACHFF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arch Biopartners EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ARCH:Canada

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.